| Regimen Name |
Indication |
|
Abemaciclib Therapy
Regimen
|
00619a
Abemaciclib in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence.
|
|
Abiraterone and Prednisolone Therapy
Regimen
|
00103a
Abiraterone is indicated in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
00103b
Treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
|
|
Abiraterone 1000mg and Prednisolone 5mg Therapy
Regimen
|
00577a
Abiraterone is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)
|
|
Afatinib Monotherapy
Regimen
|
00221a
Treatment of Epidermal Growth Factor Receptor (EGFR) TKI- naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
|
|
Acalabrutinib (Capsules) Monotherapy
Regimen
|
00656a
As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00656b
As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy
|
|
Acalabrutinib (Tablets) Monotherapy
Regimen
|
00840a
As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00840b
As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy
|
|
Alectinib Monotherapy
Regimen
|
00401a
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
00401b
As monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
|
|
Anastrozole Monotherapy
Regimen
|
00254a
Treatment of hormone receptor positive locally advanced or metastatic breast cancer in post-menopausal women.
00254b
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
00254c
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.
|
|
Apalutamide Therapy
Regimen
|
00574a
Apalutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
00574b
For the treatment of patients with metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy.
|
|
Axitinib Monotherapy
Regimen
|
00104a
Treatment of adult patients with advanced renal cell carcinoma (RCC) after failure, on a previous line of therapy, i.e. treatment with SUNItinib, or a cytokine
|
|
azaCITIDine (Oral) Monotherapy
Regimen
|
00818a
Maintenance treatment in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation (HSCT).
|
|
Pembrolizumab 200mg and Axitinib Therapy
Regimen
|
00583a
Pembrolizumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.
|
|
Bicalutamide Therapy
Regimen
|
00482a
Treatment of advanced prostate cancer in combination with luteinizing-hormone releasing hormone (LHRH) analogue therapy or surgical castration
|
|
Bortezomib , Melphalan and Prednisolone
Regimen
|
00275a
Treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
|
|
Bortezomib + Dexamethasone +Thalidomide (VTD) Induction Therapy
Regimen
|
00274a
Bortezomib, thalidomide and dexamethasone for induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation
|
|
Bortezomib, Lenalidomide and Dexamethasone (RVD) Therapy- 21 day
Regimen
|
00416a
Treatment of newly diagnosed myeloma in adult patients with high risk features
00416b
Treatment of relapsed or refractory myeloma that has received prior therapy in adult patients with high risk features
|
|
Bortezomide, Cyclophosphamide and Dexamethasone -21 day Therapy
Regimen
|
00273a
Treatment of newly diagnosed symptomatic multiple myeloma.
00273b
Treatment of relapsed/refractory multiple myeloma
|
|
Bortezomib, Lenalidomide and Dexamethasone (RVD-Lite) Induction Therapy
Regimen
|
00780a
Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible C
|
|
Bortezomib and Lenalidomide (RVD-Lite) Consolidation Therapy
Regimen
|
00781a
Treatment of newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction therapy.
|
|
Lenalidomide Maintenance Therapy (RVD-Lite)
Regimen
|
00782a
Indicated as single agent maintenance therapy in patients with newly diagnosed multiple myeloma patients who are transplant ineligible after completion of RVD-lite induction and consolidation therapy.
|
|
Bosutinib Monotherapy
Regimen
|
00224a
Treatment of adult patients with chronic phase (CP), accelerate phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotonib and dasatinib are not considered appropriate treatment options
|
|
Brigatinib Therapy
Regimen
|
00562a
For the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
00562b
Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor
|
|
Cabozantanib Therapy
Regimen
|
00518a
Treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy
|
|
Capecitabine Monotherapy
Regimen
|
00216a
Treatment of patients with locally advanced or metastatic breast cancer
00216b
Treatment of metastatic colorectal cancer.
00216c
Adjuvant treatment of patients following surgery of stage III colon cancer
00216d
Adjuvant treatment of patients following surgery of stage II colon cancer.
00216e
Adjuvant treatment of patients with metastatic colorectal cancer following complete resection
00216f
Adjuvant treatment of stage I to IIIB, triple negative breast cancer (TNBC) in patients with residual invasive disease after neoadjuvant chemotherapy treatment
|
|
Capecitabine and RT – 7 day
Regimen
|
00523a
Locally advanced pancreatic cancer after induction chemotherapy
|
|
Capecitabine and Temozolomide Therapy
Regimen
|
00505a
Treatment of patients with locally advanced or metastatic neuroendocrine tumours of the pancreas.
|
|
Capecitabine/Oxaliplatin (XELOX) Therapy
Regimen
|
00321a
Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of the primary tumour.
00321b
Treatment of advanced or metastatic colorectal cancer
00321c
Adjuvant Stage II/III gastric adenocarcinoma post D2 gastrectomy.
|
|
Capecitabine 825mg/m2 and RT–7 day
Regimen
|
00586a
Locally advanced rectal cancer
|
|
CARBOplatin and Oral Etoposide Therapy-21 days
Regimen
|
00319a
Small cell lung cancer (SCLC) extensive disease
|
|
Carfilzomib (27mg/m2 twice weekly), Lenalidomide and Dexamethasone (KRd) Therapy - 28 day
Regimen
|
00405a
Carfilzomib, lenalidomide and dexamethasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|
|
Carfilzomib and dexAMETHasone (Kd) Therapy - 28 day
Regimen
|
00566
In combination with dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|
|
Carfilzomib (56mg/m2 once weekly) Lenalidomide and dexAMETHasone (KRd) Therapy - 28 day
Regimen
|
00598a
Carfilzomib, lenalidomide and dexAMETHasone therapy is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|
|
Ceritinib Monotherapy
Regimen
|
00340a
Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib
|
|
Chlorambucil10mg/m2 Therapy
Regimen
|
00411a
Treatment of patients with low grade lymphoma.
00411b
Treatment of patients with Chronic Lymphocytic Leukaemia
|
|
CISplatin and Capecitabine Adjuvant Chemoradiation Therapy
Regimen
|
00473a
Adjuvant treatment of adult patients with resected gastric cancer stage IIA or higher and no distant metastases
|
|
CISplatin and Teysuno-28 day cycle
Regimen
|
00235a
Treatment of advanced gastric cancer when given in combination with CISplatin.
|
|
Cobimetinib and Vemurafenib Therapy
Regimen
|
00373a
Cobimetinib and vemurafenib in combination are indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
|
|
Crizotinib Monotherapy
Regimen
|
00243a
Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
00243b
The treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC)
00243c
First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)
|
|
Cyclophosphamide (Oral) Methotrexate and 5-Fluorouracil (CMF) Therapy
Regimen
|
00377a
Adjuvant treatment for breast carcinoma in patients who are considered unsuitable for anthracycline therapy
00377b
Metastatic breast carcinoma
|
|
Dabrafenib Monotherapy
Regimen
|
00237a
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation
|
|
Dacomitinib Monotherapy
Regimen
|
00565a
Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations
|
|
Darolutamide Therapy
Regimen
|
00693a
Treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.
|
|
Dexamethasone, riTUXimab and Cyclophosphamide
(DRC)Therapy
Regimen
|
00532a
Treatment of Symptomatic treatment naive or relapsed/refractory
Waldenstrom’s macroglobulinaemia
|
|
Encorafenib and Binimetinib Therapy
Regimen
|
00563a
Treatment of adult patients with advanced unresectable or metastatic)
melanoma with a BRAF V600 mutation.
|
|
Entrectinib Therapy
Regimen
|
00702a
As monotherapy for the treatment of adult patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors
|
|
Enzalutamide Monotherapy
Regimen
|
00233a
Treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after DOCEtaxel therapy.
00233b
Treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
00233c
The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)
|
|
epiRUBicin, CISplatin and Capecitabine (ECX) Therapy
Regimen
|
00380a
Perioperative treatment of resectable gastric adenocarcinoma
00380b
Perioperative treatment of resectable gastroesophageal junction adenocarcinoma
00380c
Perioperative treatment of resectable lower oesophagus adenocarcinoma
00380d
Palliative therapy for metastatic or locally advanced gastric adenocarcinoma
00380e
Palliative therapy for metastatic or locally advanced oesphagogastric adenocarcinoma
|
|
epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy
Regimen
|
00239a
Locally advanced or metastatic gastric carcinoma
00239b
Locally advanced or metastatic oesophageal carcinoma
00239c
Locally advanced or metastatic gastroesophageal carcinoma
|
|
Erlotinib Monotherapy
Regimen
|
00219a
First-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations.
00219b
Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy
00219c
Treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
|
|
Escalated Dose BEACOPP 21 day Therapy
Regimen
|
00354a
Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)
00354b
Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD
|
|
Everolimus Monotherapy
Regimen
|
00320a
Treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy
00320b
Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.
00320c
The treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal origin in adults with progressive disease
|
|
Exemestane Monotherapy
Regimen
|
00376a
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
00376b
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy.
00376c
Advanced breast cancer after relapse or disease progression in women with natural or artificially induced post menopausal endocrine status
|
|
Everolimus and Exemestane Therapy
Regimen
|
00322a
Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
|
|
Fludarabine, Cyclophosphamide and riTUXimab (FC Oral+R) Therapy
Regimen
|
00410a
Treatment of B-cell chronic lymphocytic leukaemia (CLL)
|
|
Gefitinib Monotherapy
Regimen
|
00220a
Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK
|
|
Gemcitabine (1000mg/m2) and Capecitabine (830mg/m2) Therapy - 28 days
Regimen
|
00524a
Adjuvant treatment of pancreatic adenocarcinoma after macroscopic complete resection
|
|
Gemcitabine + Capecitabine Therapy
Regimen
|
00384a
Locally advanced or metastatic pancreatic carcinoma
00384b
Locally advanced bilary tree carcinoma
|
|
Ibrutinib Therapy (CLL/ Waldenstrom's Macroglobulinaemia)
Regimen
|
00296a
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00296b
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy
00296c
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy
|
|
Ibrutinib Therapy (Mantle Cell Lymphoma)
Regimen
|
00297a
As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)
|
|
Idelalisib and Ofatumumab Therapy
Regimen
|
00390a
In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00390b
In combination with Ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies
|
|
Idelalisib and riTUXimab Therapy
Regimen
|
00389a
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00389b
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies
|
|
Idelalisib Monotherapy
Regimen
|
00291a
Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
|
|
Imatinib Therapy-GIST
Regimen
|
00335a
Treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
00335b
Adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST
|
|
Ixazomib, Lenalidomide and Dexamethasone Therapy - 28 day
Regimen
|
00516a
Ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
|
|
Lapatinib and Capecitabine
Regimen
|
00217a
Treatment of adult patients with breast cancer, whose tumours over express HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting
|
|
Larotrectinib Monotherapy- Adult
Regimen
|
00758a
For the treatment of adult patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options
|
|
Larotrectinib Monotherapy-Paediatric
Regimen
|
P00760a
For the treatment of paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,
- who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and
- who have no satisfactory treatment options
|
|
LEAM Autologous Transplant Conditioning Protocol (Lomustine, etoposide, cytarabine, melphalan)
Regimen
|
00468a
Autologous conditioning in non-Hodgkin's Lymphoma (NHL)
00468b
Autologous conditioning in Hodgkins lymphoma
|
|
Lenalidomide 25mg and dexAMETHasone Therapy - 28 day
Regimen
|
00218a
Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant
00218b
Treatment of multiple myeloma in adult patients who have received at least one prior therapy
|
|
Lenvatinib DTC Therapy
Regimen
|
00295a
Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
|
|
Lenvatinib-HCC Therapy
Regimen
|
00644a
As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy
|
|
Letrozole Monotherapy
Regimen
|
00371a
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer
00371b
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.
00371c
Advanced breast cancer after relapse or disease progression in women with natural or artificially induced post menopausal endocrine status
00371d
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
|
|
Lomustine 130mg/m2 Therapy
Regimen
|
00805a
Recurrent malignant glioma
|
|
Lorlatinib Therapy
Regimen
|
00570a
As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), following disease progression on
(i) alectinib or ceritinib as the first ALK-targeted treatment or
(ii) crizotinib and at least one other ALK-targeted treatment
|
|
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy
Regimen
|
00682a
Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction
chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
|
|
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy
Regimen
|
00683
Midostaurin is indicated in combination with intermediate dose cytarabine consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
|
|
Midostaurin Maintenance Therapy
Regimen
|
00661
Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.
|
|
mitoMYcin and Capecitabine Chemoradiation Therapy
Regimen
|
00727
Treatment of anal canal carcinoma
|
|
Modified CyBorD/ Bortezomib, Cyclophosphamide and Dexamethasone –Weekly Therapy
Regimen
|
00299a
Treatment of newly diagnosed symptomatic multiple myeloma
00299b
Treatment of relapsed/refractory multiple myeloma
|
|
Nintedanib Therapy
Regimen
|
00372a
Treatment of adult patients with locally advanced, metastatic of stage IIIB or IV, or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy
|
|
Niraparib and Abiraterone acetate (Akeega®) and prednisoLONE Therapy
Regimen
|
00848a
Niraparib in combination with abiraterone acetate (Akeega®) and predniSONE/prednisoLONE for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated
|
|
Niraparib Monotherapy
Regimen
|
00571a
As monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00571b
As monotherapy for the maintenance treatment of adult patients with platinum sensitive fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00571c
As monotherapy for the maintenance treatment of adult patients with platinum sensitive primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy
00571d
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
00571e
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) fallopian tube cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
00571f
As monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy
|
|
Obinutuzumab and Chlorambucil Therapy
Regimen
|
00286a
Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
|
|
Olaparib (Tablet) Monotherapy
Regimen
|
00588a
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) high grade epithelial ovarian cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588b
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) fallopian tube cancer who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588c
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2‐mutated (germline and/or somatic) primary peritoneal carcinoma who are in response (complete or partial) following completion of first‐line platinum based chemotherapy
00588d
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) -high grade serous epithelial ovarian cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588e
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) fallopian tube cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
00588f
Maintenance treatment of adult patients with platinum -sensitive relapsed BRCA-mutated (germline and/or somatic) primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.
|
|
Oral Etoposide Therapy
Regimen
|
00388a
Small cell lung cancer (SCLC) extensive disease in patients unsuitable for intravenous or combination chemotherapy
|
|
Oral Vinorelbine Monotherapy-7days
Regimen
|
00259a
Advanced breast cancer
00259b
Non small cell lung cancer (NSLC)
|
|
Osimertinib
Regimen
|
00353a
Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
00353b
First-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
00353c
As monotherapy for adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumour has epidermal growth factor receptor (EGFR) exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.
|
|
Palbociclib Therapy-28 day
Regimen
|
00414a
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor
00414b
Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy
|
|
Pazopanib Therapy
Regimen
|
00445a
First line treatment of advanced Renal Cell Carcinoma (RCC) in adults and for patients who have received prior cytokine therapy for advanced disease.
00445b
Treatment of adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy.
|
|
Pomalidomide and Dexamethasone
Regimen
|
00245a
Treatment in combination with dexamethasone of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
|
|
Pomalidomide, Bortezomib and dexAMETHasone (PVD) Therapy
Regimen
|
00601a
Pomalidomide in combination with bortezomib and dexAMETHasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment including lenalidomide
|
|
Ponatinib Therapy
Regimen
|
00302a
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
00302b
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
|
|
Procarbazine Lomustine and VinCRIStine (PCV) Therapy
Regimen
|
00379a
Adjuvant treatment of Grade II glioma administered after radiotherapy
00379b
Palliative treatment for recurrent high grade gliomas
|
|
Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days
Regimen
|
00658a
Adjuvant treatment of Grade II glioma administered after radiotherapy.
|
|
RiTUXimab, Cyclophosphamide, Etoposide, Vincristine Prednisolone (R-CEOP) Therapy – 21 days
Regimen
|
00510a
Treatment of Non Hodgkin CD20 positive Lymphoma for patients not
|
|
Regorafenib Monotherapy
Regimen
|
00244a
Treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy.
00244b
Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib
|
|
Relugolix Therapy
Regimen
|
00830a
Treatment of adult patients with advanced hormone-sensitive prostate cancer (HSPC).
|
|
Ribociclib Therapy-28 day
Regimen
|
00525a
Treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine-based therapy in combination with an aromatase inhibitor.
00525b
Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine based therapy or in women who have received prior endocrine therapy.
In pre or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone releasing hormone (LHRH) agonist.
|
|
Ruxolitinib Monotherapy
Regimen
|
00229a
Treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (chronic idiopathic myelofibrosis)
00229b
Post polycythaemia vera myelofibrosis
00229c
Post essential thrombocythaemia myelofibrosis
|
|
Sorafenib Therapy
Regimen
|
00294a
Treatment of hepatocellular carcinoma (HCC).
00294b
Treatment of patients with advanced renal cell carcinoma (RCC) who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
00294c
Treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
|
|
SUNitnib 37.5mg Therapy
Regimen
|
00327a
Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults
|
|
SUNitinib 50mg Therapy
Regimen
|
00325a
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
00325b
Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults
|
|
SUNitinib 50mg (21 Days) Therapy
Regimen
|
00719a
Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.
00719b
Treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults
|
|
Talazoparib
Regimen
|
00605a
Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy or be considered unsuitable for endocrine-based therapy.
|
|
Tamoxifen Monotherapy
Regimen
|
00253a
Adjuvant treatment of oestrogen receptor positive breast cancer in pre- or post-menopausal women.
00253b
Treatment of oestrogen receptor positive advanced breast cancer in pre- or post-menopausal women
|
|
Temozolomide Recurrent Therapy
Regimen
|
00342a
Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma,showing recurrence or progression after standard therapy.
|
|
Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years
Regimen
|
00461a
Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide.
|
|
Temozolomide with RT and Adjuvant Therapy
Regimen
|
00334a
Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation.
|
|
Tivozanib Therapy
Regimen
|
00564a
Tivozanib for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC
|
|
Topotecan Oral Monotherapy
Regimen
|
00587a
Treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first –line regimen is not considered appropriate
|
|
Trametinib and Dabrafenib Therapy
Regimen
|
00415a
Treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
|
|
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy
Regimen
|
00356a
Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL)
|
|
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy
Regimen
|
00357a
Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356
|
|
Tretinoin (ATRA)/Idarubicin (PETHEMA AIDA) Induction Therapy
Regimen
|
00366a
Treatment of patients with newly diagnosed Acute Promyelocytic Leukaemia (APL)
|
|
Trifluridine and Tipiracil (Lonsurf®) Therapy
Regimen
|
00382a
Treatment of adult patients with metastatic colorectal cancer who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine, oxaliplatin and irinotecan based therapies, anti-VEGF and anti-EGFR agents.
|
|
Vandetanib Monotherapy
Regimen
|
00242a
Treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
|
|
Vemurafenib Monotherapy
Regimen
|
00102a
Treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
|
|
Venetoclax Monotherapy
Regimen
|
00400a
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor
00400b
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor
|
|
Venetoclax and riTUXimab Therapy
Regimen
|
00575a
Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
|
|
Vismodegib Monotherapy
Regimen
|
00236a
Treatment of adult patients with symptomatic metastatic basal cell carcinoma (MBCC)
00236b
Treatment of adult patients with local advanced basal cell carcinoma inappropriate for surgery or radiotherapy
|
|
Zanubrutinib Therapy
Regimen
|
00708
As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy or
as first line treatment for patients unsuitable for chemo-immunotherapy
|
